Founded in 1996, Novartis Venture Fund is a corporate venture capital arm of Novartis headquartered in Basel, Switzerland. The firm seeks to invest in the life sciences, oncology, biotechnology, and digital health sectors. The firm has an additional presence in Cambridge, Massachusetts.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
---|---|---|---|---|---|---|
Exo Therapeutics | 16-Dec-2020 | Early Stage VC | 0000 | Drug Discovery | Startup | 00000 000000 00.0 |
0000 000000000 | 10-Dec-2020 | 00000 00000 | 0000 | Other Healthcare Services | Startup | 00000 00000 00.0 |
0000000 | 10-Nov-2020 | 00000 00000 | 000.00 | Drug Discovery | Generating Revenue | 0000 0000000 |
000000 00000000000 | 13-Oct-2020 | 00000 00000 | 000.00 | Drug Discovery | Product Development | 0000 0000000 |
0000 (000000000000 | 21-Sep-2020 | 00000 00000 | 0000 | Biotechnology | Generating Revenue | 000000 0000000000 |
000000 000 | 14-Sep-2020 | 00000 00000 | 0000 | Biotechnology | Clinical Trials - Phase 1 | |
0000000 00 | 20-Aug-2020 | 00000 00000 | 0000 | Other Healthcare Services | Generating Revenue | |
0000000-000 | 18-Aug-2020 | 00000 00000 | 0000 | Biotechnology | Generating Revenue | |
GentiBio | 05-Aug-2020 | Seed Round | 0000 | Drug Discovery | Startup | 000000 0000000000 |
FoRx Therapeutics | 22-Apr-2020 | Seed Round | 000.00 | Drug Discovery | Startup | 0000000 00000000000000 00.0 |
Company Name | Exit Date | Exit Type | Exit Size |
---|---|---|---|
Forma Therapeutics | 11-Dec-2020 | Public Investment 2nd Offering | 00000 |
0000000000 0000000 | 07-Oct-2020 | 000000000 00000000 | 000.00 |
000000000 | 21-Sep-2020 | 000000000000000000 | 00000 |
0000000 0000000000 | 24-Jul-2020 | 000 | 00000 |
000000 | 26-Jun-2020 | 000 | 00000 |
00000 000000000000 | 19-Jun-2020 | 000 | 00000 |
0000000 0000000 00 | 15-Jun-2020 | 0000000000: 000000 | |
0000000000 | 01-Apr-2020 | 000000000000000000 | |
Microchips Biotech | 20-Nov-2019 | Merger/Acquisition | |
Galera Therapeutics | 07-Nov-2019 | IPO | 0000 |
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialName | Title | Deals | Funds | Boards | Office |
---|---|---|---|---|---|
Anja König Ph.D | Global Head | 00 | 0 | 0 | Basel, Switzerland |
Bart Dzikowski | Managing Director & Head of Transactions & Legal | 0 | Basel, Switzerland | ||
Aaron Nelson Ph.D | Managing Director | 0 | 0 | Cambridge, MA | |
Florian Muellershausen Ph.D | Managing Director | 0 | 0 | Basel, Switzerland | |
Laura Brass Ph.D | Managing Director | 0 | 0 | 0 | Cambridge, MA |
Name | With | Exits | Lead Partner | Series | Industry |
---|---|---|---|---|---|
Johnson & Johnson Innovation - JJDC | 6 | 0 |
![]() |
![]() |
|
AbbVie Ventures | 0 | 0 |
![]() |
![]() |
|
Novo Holdings | 0 | 00 |
![]() |
![]() |
|
OrbiMed | 0 | 0 |
![]() |
![]() |
|
Life Sciences Partners | 0 | 0 |
![]() |
![]() |